451 related articles for article (PubMed ID: 23208046)
1. [MITO-Porter; a cutting-edge technology for mitochondrial gene therapy].
Furukawa R; Yamada Y; Harashima H
Yakugaku Zasshi; 2012; 132(12):1389-98. PubMed ID: 23208046
[TBL] [Abstract][Full Text] [Related]
2. An analysis of membrane fusion between mitochondrial double membranes and MITO-Porter, mitochondrial fusogenic vesicles.
Yamada Y; Fukuda Y; Harashima H
Mitochondrion; 2015 Sep; 24():50-5. PubMed ID: 26188112
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial transgene expression via an artificial mitochondrial DNA vector in cells from a patient with a mitochondrial disease.
Ishikawa T; Somiya K; Munechika R; Harashima H; Yamada Y
J Control Release; 2018 Mar; 274():109-117. PubMed ID: 29408532
[TBL] [Abstract][Full Text] [Related]
4. Targeting the mitochondrial genome via a dual function MITO-Porter: evaluation of mtDNA levels and mitochondrial function.
Yamada Y; Harashima H
Methods Mol Biol; 2015; 1265():123-33. PubMed ID: 25634272
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial matrix delivery using MITO-Porter, a liposome-based carrier that specifies fusion with mitochondrial membranes.
Yasuzaki Y; Yamada Y; Harashima H
Biochem Biophys Res Commun; 2010 Jun; 397(2):181-6. PubMed ID: 20580633
[TBL] [Abstract][Full Text] [Related]
6. Targeting the Mitochondrial Genome Via a MITO-Porter : Evaluation of mtDNA and mtRNA Levels and Mitochondrial Function.
Yamada Y; Harashima H
Methods Mol Biol; 2021; 2275():227-245. PubMed ID: 34118041
[TBL] [Abstract][Full Text] [Related]
7. A synthetic mitochondrial-based vector for therapeutic purposes.
Renteln M
Med Hypotheses; 2018 Aug; 117():28-30. PubMed ID: 30077190
[TBL] [Abstract][Full Text] [Related]
8. Delivery of bioactive molecules to the mitochondrial genome using a membrane-fusing, liposome-based carrier, DF-MITO-Porter.
Yamada Y; Harashima H
Biomaterials; 2012 Feb; 33(5):1589-95. PubMed ID: 22105068
[TBL] [Abstract][Full Text] [Related]
9. The use of a MITO-Porter to deliver exogenous therapeutic RNA to a mitochondrial disease's cell with a A1555G mutation in the mitochondrial 12S rRNA gene results in an increase in mitochondrial respiratory activity.
Yamada Y; Maruyama M; Kita T; Usami SI; Kitajiri SI; Harashima H
Mitochondrion; 2020 Nov; 55():134-144. PubMed ID: 33035688
[TBL] [Abstract][Full Text] [Related]
10. [Development of the MITO-porter, a nano device for mitochondrial drug delivery via membrane fusion].
Yamada Y
Yakugaku Zasshi; 2014; 134(11):1143-55. PubMed ID: 25366911
[TBL] [Abstract][Full Text] [Related]
11. Dual function MITO-Porter, a nano carrier integrating both efficient cytoplasmic delivery and mitochondrial macromolecule delivery.
Yamada Y; Furukawa R; Yasuzaki Y; Harashima H
Mol Ther; 2011 Aug; 19(8):1449-56. PubMed ID: 21694702
[TBL] [Abstract][Full Text] [Related]
12. Validation of a mitochondrial RNA therapeutic strategy using fibroblasts from a Leigh syndrome patient with a mutation in the mitochondrial ND3 gene.
Yamada Y; Somiya K; Miyauchi A; Osaka H; Harashima H
Sci Rep; 2020 May; 10(1):7511. PubMed ID: 32371897
[TBL] [Abstract][Full Text] [Related]
13. Development of mitochondrial gene replacement therapy.
Khan SM; Bennett JP
J Bioenerg Biomembr; 2004 Aug; 36(4):387-93. PubMed ID: 15377877
[TBL] [Abstract][Full Text] [Related]
14. MITO-Porter for Mitochondrial Delivery and Mitochondrial Functional Analysis.
Yamada Y; Harashima H
Handb Exp Pharmacol; 2017; 240():457-472. PubMed ID: 27830347
[TBL] [Abstract][Full Text] [Related]
15. Transmitochondrial mice as models for mitochondrial DNA-based diseases.
Nakada K; Hayashi J
Exp Anim; 2011; 60(5):421-31. PubMed ID: 22041279
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial dynamics and aging: Mitochondrial interaction preventing individuals from expression of respiratory deficiency caused by mutant mtDNA.
Sato A; Nakada K; Hayashi J
Biochim Biophys Acta; 2006; 1763(5-6):473-81. PubMed ID: 16624428
[TBL] [Abstract][Full Text] [Related]
17. Targeted mitochondrial delivery of antisense RNA-containing nanoparticles by a MITO-Porter for safe and efficient mitochondrial gene silencing.
Kawamura E; Hibino M; Harashima H; Yamada Y
Mitochondrion; 2019 Nov; 49():178-188. PubMed ID: 31472283
[TBL] [Abstract][Full Text] [Related]
18. MitoTALEN: A General Approach to Reduce Mutant mtDNA Loads and Restore Oxidative Phosphorylation Function in Mitochondrial Diseases.
Hashimoto M; Bacman SR; Peralta S; Falk MJ; Chomyn A; Chan DC; Williams SL; Moraes CT
Mol Ther; 2015 Oct; 23(10):1592-9. PubMed ID: 26159306
[TBL] [Abstract][Full Text] [Related]
19. Approaches and limitations to gene therapy for mitochondrial diseases.
Owen R; Flotte TR
Antioxid Redox Signal; 2001 Jun; 3(3):451-60. PubMed ID: 11491656
[TBL] [Abstract][Full Text] [Related]
20. [Targeting mitochondria: innovation from mitochondrial drug delivery system (DDS) to mitochondrial medicine].
Yamada Y; Harashima H
Yakugaku Zasshi; 2012; 132(10):1111-8. PubMed ID: 23037696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
